Please assess the completion status of the following clinical trial:

Trial Title: Patient-reported Outcomes for Sarecycline Effectiveness and Safety (PROSES)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patient Inclusion Criteria:~* Male or female, aged 9 years and above~* Has facial non-nodular AV with IGA score of moderate or severe~* Considered as a potential candidate for sarecycline (Seysara®) treatment, per clinician judgment~Caregiver Inclusion Criteria:~* Primary caregiver of the study-eligible patient~* Male or female, aged 18 years and above~Exclusion Criteria:~* Patients with any known resistance to other tetracyclines~* Patients with any dermatological or physical condition of the face that could interfere with the AV clinical evaluations.~* Patients with any history of allergy to tetracycline-class antibiotics, pseudomembranous colitis or antibiotic-associated colitis.~* Unable to comply with the requirements of the study or patients who in the opinion of the Site Investigator should not participate in the study~Other protocol defined Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sarecycline (Type: None): Eligible patients prescribed with commercially available sarecycline will be followed-up for 12 weeks post-initiation of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).